Antimalarial Allergy: HCQ Rash, Fansidar SJS/TEN & G6PD Screening

Potentially, yes. A validated two-stage desensitization protocol achieves 92% success in enabling HCQ-allergic lupus patients to resume therapy, according to Tal et al. published in Lupus in 2018. Because HCQ is foundational to SLE management — reducing lupus flares, protecting kidneys and other organs, lowering cardiovascular thrombosis risk, and extending survival — permanent discontinuation carries real risks. The desensitization protocol is performed under allergist-rheumatology coordination. Discuss candidacy with your rheumatologist and allergist before permanently discontinuing HCQ based on a rash alone.

Sulfadoxine-pyrimethamine (Fansidar) was withdrawn from routine malaria prophylaxis in 1986 after Miller et al. reported fatal Stevens-Johnson syndrome and toxic epidermal necrolysis at a rate of approximately 1 per 5,000 to 8,000 non-immune travelers. The sulfadoxine component carries the immunogenic arylamine group at N4 that is characteristic of sulfonamide antibiotic allergy — the same mechanism behind TMP-SMX SCAR reactions. Fansidar remains available for single-dose malaria treatment and intermittent preventive therapy in pregnancy in endemic settings, where the benefit-risk calculation is fundamentally different from prophylaxis in non-immune travelers.

No. Mefloquine neuropsychiatric effects — anxiety, depression, vivid nightmares, insomnia, and rarely psychosis or seizures — are idiosyncratic pharmacologic CNS phenomena, not immune-mediated allergy. The exact mechanism is not fully characterized but is believed to involve mefloquine's CNS penetration and effects on neurotransmitter systems. The FDA added a boxed warning in 2013 requiring prescribers to counsel patients about these potential effects. These reactions do not indicate allergy to mefloquine or cross-allergy to other antimalarials. Alternative prophylaxis options for travelers include atovaquone-proguanil (Malarone) and doxycycline.

Primaquine and tafenoquine are 8-aminoquinolines that generate reactive oxygen metabolites during their oxidative metabolism. In patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency — a common X-linked genetic condition affecting approximately 400 million people worldwide, especially in populations from Africa, the Mediterranean, and Southeast Asia — this oxidative stress overwhelms the compromised antioxidant capacity of red blood cells, causing potentially life-threatening hemolytic anemia. FDA prescribing labeling mandates G6PD testing before prescribing either drug. This is pharmacogenomic toxicity screening, not allergy testing — the reaction is a predictable pharmacologic effect in G6PD-deficient individuals.

Chloroquine causes intense generalized pruritus in many dark-skinned individuals taking the drug for malaria — a side effect that has been particularly well-documented in West African populations and significantly limits chloroquine adherence in these patients. This is not an allergic reaction. Liu et al. identified the MrgprA3 receptor on sensory neurons as the mediator of chloroquine-induced pruritus in a landmark 2009 Cell paper — this is a non-histaminergic pruritoceptor pathway, which explains why standard antihistamines are often ineffective. Despite being highly distressing, this pharmacologic side effect does not represent immune sensitization and does not predict allergy to other antimalarials.

For travelers who cannot take chloroquine or mefloquine, atovaquone-proguanil (Malarone) is the preferred standard-of-care alternative — it has a relatively low hypersensitivity signal and good tolerability for most routes. Doxycycline is another evidence-based option for most malaria-endemic regions but carries phototoxicity risk that limits use in travelers with high sun exposure. For patients with confirmed sulfonamide allergy, Fansidar is contraindicated due to the sulfadoxine component. Artemisinin-based combination therapies are used for active malaria treatment and have a very low hypersensitivity profile. Your travel medicine specialist can select the safest regimen based on destination and allergy history.

Distinguishing hydroxychloroquine-induced rash from lupus skin manifestations is a genuine clinical challenge because both present as skin involvement in a patient with SLE. Lupus-specific rashes include malar (butterfly) rash, discoid lesions, and photosensitive subacute cutaneous lupus erythematosus (SCLE). HCQ drug rash typically presents as a non-specific maculopapular exanthem or urticarial eruption that temporally correlates with starting or dose-increasing HCQ. Lupus activity markers (anti-dsDNA, complement levels, disease activity scoring) can help attribute the rash — if lupus markers are flaring, the rash may be lupus rather than HCQ allergy. A dermatologist or rheumatologist familiar with lupus skin disease should evaluate the presentation.

No. Chloroquine and hydroxychloroquine retinal toxicity — specifically bull's-eye maculopathy — is a dose-dependent and duration-dependent pharmacologic effect, not an allergic reaction. It is associated with cumulative doses exceeding 5 mg per kg of actual body weight per day and treatment durations beyond 5 years. The American Academy of Ophthalmology recommends annual retinal screening with spectral-domain OCT and visual field testing after 5 years of HCQ use. Retinal toxicity is a pharmacologic concern that should prompt dose adjustment, not drug discontinuation in most cases, and is distinct from immune-mediated drug allergy.